Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
ACS Chemical Biology|December 19, 2024
Multimodal Blood-Based Biomarker Panel Reveals Altered Lysosomal Ionic Content in Alzheimer's DiseaseSenthilkumar Deivasigamani, Shareefa Thekkan, Hernando M Vergara, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 15, 2017
TMEM175 deficiency impairs lysosomal and mitochondrial function and increases α-synuclein aggregationSarah Jinn, Robert E Drolet, Paige E Cramer, et al.
Neurobiology of Disease|September 12, 2021
A novel glucosylceramide synthase inhibitor attenuates alpha synuclein pathology and lysosomal dysfunction in preclinical models of synucleinopathyMali Cosden, Sarah Jinn, Lihang Yao, et al.
Bioorganic & Medicinal Chemistry Letters|April 24, 2016
Potent, selective and orally bioavailable leucine-rich repeat kinase 2 (LRRK2) inhibitorsThomas J Greshock, John M Sanders, Robert E Drolet, et al.
Plos One|June 9, 2021
Decreased glucocerebrosidase activity and substrate accumulation of glycosphingolipids in a novel GBA1 D409V knock-in mouse modelNicole K Polinski, Terina N Martinez, Alexander Gorodinsky, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 26, 2025
BiomarkersWang Yuchuan, Helen J Mitchell, Susi Lee, et al.
ACS Medicinal Chemistry Letters|January 17, 2024
Fluorinated Isoindolinone-Based Glucosylceramide Synthase Inhibitors with Low Human Dose ProjectionsH Marie Loughran, Kathy M Schirripa, Anthony J Roecker, et al.
ACS Medicinal Chemistry Letters|February 16, 2023
Pyrazole Ureas as Low Dose, CNS Penetrant Glucosylceramide Synthase Inhibitors for the Treatment of Parkinson's DiseaseAnthony J Roecker, Kathy M Schirripa, H Marie Loughran, et al.
ACS Medicinal Chemistry Letters|August 16, 2023
Discovery of MK-8768, a Potent and Selective mGluR2 Negative Allosteric ModulatorMichael T Rudd, Peter J Manley, Barbara Hanney, et al.
Journal of Medicinal Chemistry|March 1, 2017
Discovery of a 3-(4-Pyrimidinyl) Indazole (MLi-2), an Orally Available and Selective Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitor that Reduces Brain Kinase ActivityJack D Scott, Duane E DeMong, Thomas J Greshock, et al.
Pageof 2